TY - JOUR T1 - Reduced Phosphodiesterase 3 Activity and Phosphodiesterase 3A Level in Synthetic Vascular Smooth Muscle Cells: Implications for Use of Phosphodiesterase 3 Inhibitors in Cardiovascular Tissues JF - Molecular Pharmacology JO - Mol Pharmacol SP - 1033 LP - 1040 DO - 10.1124/mol.61.5.1033 VL - 61 IS - 5 AU - Heather A. Dunkerley AU - Douglas G. Tilley AU - Daniel Palmer AU - Hanguan Liu AU - Sandra L. Jimmo AU - Donald H. Maurice Y1 - 2002/05/01 UR - http://molpharm.aspetjournals.org/content/61/5/1033.abstract N2 - Vascular smooth muscle cells (VSMC) in situ function to control contraction and are said to express a contractile phenotype. However, during development or in response to vascular damage, VSMC proliferate and express a more synthetic phenotype. A survey of literature values for contractile and synthetic VSMC phosphodiesterase (PDE) 3 and PDE4 activities identified a marked difference in the PDE3 and PDE4 activities of these cells. In this study, a comparison of PDE3 and PDE4 activities in contractile and synthetic VSMC demonstrates that a reduced PDE3/PDE4 activity ratio in synthetic VSMC correlates with a reduced PDE3 activity and is associated with marked reductions in PDE3A mRNA and protein levels. Because we show that similar reductions in PDE3 activity and PDE3A levels occur upon culture of human aortic VSMC and that this phenomenon associates with the phenotypic switch that occurs to VSMC in response to vascular damage, our findings are presented in the context that PDE3 inhibition might be expected to selectively alter functions of contractile VSMC. ER -